Results 221 to 230 of about 204,259 (398)

Comparison of a new microcrystalline dicoumarol preparation with warfarin under routine treatment conditions. [PDF]

, 1979
D. Lockner, Claudia Paul
openalex   +1 more source

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin

Drug Design, Development and Therapy, 2015
Jin Ah Jung,1 Soo-Yun Lee,2 Tae-Eun Kim,3 Jung-Ryul Kim,1 Chin Kim,4 Wooseong Huh,1,5 Jae-Wook Ko1,2 1Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 2Department of Health Sciences and Technology, Samsung Advanced Institute ...
Jung JA, Lee SY, Kim TE, Kim JR, Kim C, Huh W, Ko JW   +6 more
doaj  

Letter: Potentiation of warfarin by co-trimoxazole. [PDF]

, 1975
J De Swiet
openalex   +1 more source

Dicoumarol and warfarin [PDF]

Heart, 1991
openaire   +2 more sources

Pathogenic variants in chromatin‐related genes: Linking immune dysregulation to neuroregression and acute neuropsychiatric disorders

Developmental Medicine &Child Neurology, EarlyView.
Chromatin machinery influences how DNA is ‘wrapped’ around histones in the nucleosome of immune and brain cells. Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16299 Abstract We report eight children with de novo pathogenic DNA variants in chromatin‐related genes: MORC2, CHD7, KANSL1, KMT2D, ZMYND11, HIST1HIE, EP300, and KMT2B.
Russell C. Dale, Shekeeb Mohammad, Velda X. Han, Hiroya Nishida, Himanshu Goel, Stuart G. Tangye, Georgina Hollway, Esther Tantsis, Deepak Gill, Shrujna Patel, Chromatin Immune‐Brain Group, Michael Lonergan, Melanie Wong, Kavitha Kothur, Erica Tsang   +14 more
wiley   +1 more source

Bound to bleed: How altered albumin binding may dictate warfarin treatment outcome

International Journal of Cardiology: Heart & Vasculature, 2019
Although non-vitamin-K anticoagulants are now the preferred option for stroke prevention in atrial fibrillation (AF), warfarin is still used in a significant number of patients.
Anke C. Fender, Dobromir Dobrev
doaj  

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

Clinical pharmacology and therapy, 2017
Julie A. Johnson, K. Caudle, L. Gong, Michelle Whirl‐Carrillo, C. Stein, S. Scott, M. M. Lee, B. Gage, S. Kimmel, M. Perera, Jeffrey L. Anderson, M. Pirmohamed, T. Klein, N. Limdi, L. Cavallari, M. Wadelius   +15 more
semanticscholar   +1 more source

Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures

Haemophilia, EarlyView.
ABSTRACT Introduction Patients with severe Factor XI deficiency face unique challenges during urological procedures due to an elevated risk of bleeding, balanced against the use of tranexamic acid (TXA), which may form blood clots. Given the limitations associated with plasma‐based treatment, there have been reports of successful and safe off‐label use
Neta Sternbach, Yaron Ehrlich, Anfisa Stenevsky, Daniel Saidian, Darawsha Abd Elhalim, Jack Baniel, Pia Raanani, Galia Spectre   +7 more
wiley   +1 more source

Mechanism of exacerbation of traumatic brain injury under warfarin anticoagulation in male mice.

PLoS ONE
IntroductionTraumatic brain injury (TBI) is exacerbated in patients on antithrombotic medications, with warfarin leading to increased bleeding in some cases.
Yuki Tatara, Ken-Ichiro Nakao, Ryo Shimada, Kazuhiko Kibayashi   +3 more
doaj   +1 more source

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source